Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways [v1; ref status: indexed, http://f1000r.es/x3]

Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways [v1; ref status: indexed, http://f1000r.es/x3]

Human mesoangioblasts are currently in a phase I/II clinical trial for the treatment of patients with Duchenne muscular dystrophy. However, limitations associated with the finite life span of these cells combined with the significant numbers of mesoangioblasts required to treat all of the skeletal m...

Full description

Bibliographic Details
Main Authors: Ou Li, Karen English, Rossana Tonlorenzi, Giulio Cossu, Francesco Saverio Tedesco, Kathryn J Wood
Format: Article
Language:English
Published: F1000 Research Ltd 2013-01-01
Series:F1000Research
Subjects:
Clinical Immunology
Immune Response
Musculoskeletal Repair & Regeneration
Non-hematopoietic Stem Cells
Stem Cells & Regeneration
Online Access:http://f1000research.com/articles/2-24/v1

Internet

http://f1000research.com/articles/2-24/v1

Similar Items